…, starting in January, the consortium running the Kenema lab inked a $140 million deal with Department of Defense and a pharma company called Tekmira to conduct Phase I Ebola vaccine trails at Kenema on humans (see ” Tekmira Doses First Subject in Human Clinical Trial of TKM-Ebola” press release)
Is there precedent for infecting subjects in order to run drug trials? Absolutely. A 2008 published case involved Polish homeless people who were experimented upon with bird flu vaccine.
VANCOUVER, British Columbia, Jan. 14, 2014 (GLOBE NEWSWIRE) — Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that it has dosed the first subject in a Phase I human clinical trial of TKM-Ebola, an anti-Ebola viral therapeutic that is being developed under a US$140 million contract with the U.S. Department of Defense. read more
…scientists were working with anthrax, cholera, salmonella, botulinum, thallium, E. coli, ricin, organophosphates, necrotizing fasciitis, hepatitis A, and H.I.V., as well as nerve gases (Sarin, VX) and the Ebola, Marburg, and Rift Valley hemorrhagic-fever viruses. They were producing crude toxins (and some strange delivery systems) for use by the military and police, and they were genetically engineering extremely dangerous new organismscreating, that is, biological weapons. read more
A thousand more vials of human blood with Ebola in them are sitting in freezers in Kenema waiting for bureaucratic clearance so that they can be flown to Harvard and sequenced in the machines, and scientists can see what the swarm has been doing more recently. read more
Human ebola virus species and compositions and methods thereof